Aurinia Pharmaceuticals Inc (AUPH) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Aurinia Pharmaceuticals Inc (AUPH) has a cash flow conversion efficiency ratio of 0.057x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($32.56 Million) by net assets ($567.63 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Aurinia Pharmaceuticals Inc - Cash Flow Conversion Efficiency Trend (1998–2025)
This chart illustrates how Aurinia Pharmaceuticals Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read AUPH liabilities breakdown for a breakdown of total debt and financial obligations.
Aurinia Pharmaceuticals Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Aurinia Pharmaceuticals Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Shanghai QiFan Cable Co Ltd
SHG:605222
|
-0.047x |
|
Nanjing King-friend Biochemical Pharmaceutical Co Ltd
SHG:603707
|
0.072x |
|
Global Net Lease, Inc.
NYSE:GNL
|
0.027x |
|
Hexing Electrical Co Ltd
SHG:603556
|
0.023x |
|
Autohome Inc
NYSE:ATHM
|
0.001x |
|
BaoViet Holdings
VN:BVH
|
-0.103x |
|
TriNet Group Inc
NYSE:TNET
|
1.795x |
|
NOS S.G.P.S. S.A.
LS:NOS
|
0.145x |
Annual Cash Flow Conversion Efficiency for Aurinia Pharmaceuticals Inc (1998–2025)
The table below shows the annual cash flow conversion efficiency of Aurinia Pharmaceuticals Inc from 1998 to 2025. For the full company profile with market capitalisation and key ratios, see Aurinia Pharmaceuticals Inc (AUPH) market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $581.33 Million | $135.66 Million | 0.233x | +98.45% |
| 2024-12-31 | $377.48 Million | $44.39 Million | 0.118x | +232.82% |
| 2023-12-31 | $377.95 Million | $-33.46 Million | -0.089x | +54.87% |
| 2022-12-31 | $405.44 Million | $-79.53 Million | -0.196x | +40.40% |
| 2021-12-31 | $479.09 Million | $-157.69 Million | -0.329x | -92.12% |
| 2020-12-31 | $407.75 Million | $-69.86 Million | -0.171x | +19.54% |
| 2019-12-31 | $298.60 Million | $-63.59 Million | -0.213x | +53.55% |
| 2018-12-31 | $112.58 Million | $-51.61 Million | -0.458x | -84.57% |
| 2017-12-31 | $165.74 Million | $-41.17 Million | -0.248x | +52.28% |
| 2016-12-31 | $35.95 Million | $-18.71 Million | -0.521x | +41.51% |
| 2015-12-31 | $19.96 Million | $-17.77 Million | -0.890x | -137.47% |
| 2014-12-31 | $45.11 Million | $-16.90 Million | -0.375x | -10.20% |
| 2013-12-31 | $13.30 Million | $-4.52 Million | -0.340x | -111.01% |
| 2012-12-31 | $-2.12 Million | $-6.55 Million | 3.090x | +1561.34% |
| 2011-12-31 | $6.41 Million | $-1.36 Million | -0.211x | +69.06% |
| 2010-12-31 | $6.35 Million | $-4.34 Million | -0.683x | +68.57% |
| 2009-12-31 | $4.81 Million | $-10.46 Million | -2.175x | +1.59% |
| 2008-12-31 | $7.87 Million | $-17.39 Million | -2.210x | -120.61% |
| 2007-12-31 | $28.41 Million | $-28.46 Million | -1.002x | +3.95% |
| 2006-12-31 | $20.17 Million | $-21.03 Million | -1.043x | -108.06% |
| 2005-12-31 | $42.36 Million | $-21.23 Million | -0.501x | -29.84% |
| 2004-12-31 | $52.20 Million | $-20.15 Million | -0.386x | -415.36% |
| 2003-12-31 | $68.54 Million | $-5.13 Million | -0.075x | -319.16% |
| 2002-12-31 | $47.56 Million | $-849.90K | -0.018x | +91.30% |
| 2001-12-31 | $35.28 Million | $-7.25 Million | -0.205x | +54.55% |
| 2000-12-31 | $12.76 Million | $-5.77 Million | -0.452x | -6.20% |
| 1999-12-31 | $3.19 Million | $-1.36 Million | -0.426x | -120.49% |
| 1998-12-31 | $-846.35K | $-1.76 Million | 2.077x | -- |
About Aurinia Pharmaceuticals Inc
Aurinia Pharmaceuticals Inc., a biopharmaceutical company, engages in delivering therapies to people living with autoimmune diseases with high unmet medical needs in the United States and Japan. The company offers LUPKYNIS (voclosporin), an oral therapy for the treatment of adult patients with active lupus nephritis. It also develops aritinercept, a dual inhibitor of B cell-activating factor and … Read more